title: Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
abstract: OBJECTIVE
  To evaluate the effectiveness and the safety of danaparoid sodium in the treatment of critically ill patients with standard unfractionated heparin-induced thrombocytopenia (HIT) or low-molecular-weight HIT.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  Retrospective analysis of 42 consecutive critically ill patients who were admitted for HIT between October 1992 and February 1997 and were treated either with therapeutic or prophylactic doses of danaparoid sodium.
  
  
  RESULTS
  Among the 26 patients treated with therapeutic doses, neither new thrombotic complications nor thrombosis extension was clinically suspected. Two deaths were directly related to lower limb acute arterial thrombosis associated with HIT. Two major hemorrhagic complications were observed when aspirin in addition to danaparoid sodium was administered. When danaparoid sodium was used in prophylactic doses (20 courses of treatment) to prevent either postsurgical or medical thrombotic complications, no thrombotic event was observed. No death related to HIT or danaparoid sodium treatment was observed. One aggravation of a postsurgical cerebral lesion was observed. During danaparoid sodium treatment, a persistence or a recurrence of thrombocytopenia was observed in 6.5% of patients without thrombotic complications.
  
  
  CONCLUSIONS
  Danaparoid sodium appears to be an efficient and safe treatment in critically ill patients with HIT. The concomitant use of aspirin in addition to danaparoid sodium seems to represent an important additional hemorrhagic risk that should be avoided in patient management.
authors.affiliation: Department of Hematology, Hopital Nord CHRU, Saint-Etienne, France.
authors.forename: B
authors.initials: B
authors.lastname: Tardy-Poncet
authors.forename: B
authors.initials: B
authors.lastname: Tardy
authors.forename: J
authors.initials: J
authors.lastname: Reynaud
authors.forename: P
authors.initials: P
authors.lastname: Mahul
authors.forename: P
authors.initials: P
authors.lastname: Mismetti
authors.forename: E
authors.initials: E
authors.lastname: Mazet
authors.forename: D
authors.initials: D
authors.lastname: Guyotat
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects*; D001241:Aspirin / Q000627:therapeutic use; D001779:Blood Coagulation Factors / Q000378:metabolism; D002809:Chondroitin Sulfates / Q000008:administration & dosage / Q000627:therapeutic use*; D016638:Critical Illness; D003871:Dermatan Sulfate / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010976:Platelet Count; D012008:Recurrence; D012189:Retrospective Studies; D012449:Safety; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D001241:Aspirin; D001779:Blood Coagulation Factors; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005343:Fibrinolytic Agents; D006493:Heparin; D006497:Heparan Sulfate; D010975:Platelet Aggregation Inhibitors; C035838:danaparoid